Tudor Investment Corp
PTGX icon

Tudor Investment Corp’s Protagonist Therapeutics PTGX Stock Holding History

Tudor Investment Corp’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,718
Closed -$683K – 4153
2025
Q4 		$674K Buy
+7,718
New +$632K ﹤0.01% 2542
2025
Q2 		– Sell
-42,583
Closed -$2.06M – 3662
2025
Q1 		$2.06M Buy
+42,583
New +$1.78M 0.01% 1329
2024
Q4 		– Sell
-13,858
Closed -$624K – 3410
2024
Q3 		$624K Buy
+13,858
New +$560K ﹤0.01% 1899
2024
Q2 		– Sell
-22,510
Closed -$651K – 2706
2024
Q1 		$651K Sell
22,510
-6,276
-22% -$171K ﹤0.01% 1531
2023
Q4 		$660K Buy
+28,786
New +$504K 0.01% 1642
2023
Q3 		– Sell
-33,338
Closed -$921K – 2750
2023
Q2 		$921K Sell
33,338
-4,002
-11% -$100K 0.01% 1362
2023
Q1 		$859K Buy
+37,340
New +$627K 0.01% 1287
2022
Q4 		– Sell
-24,332
Closed -$205K – 2764
2022
Q3 		$205K Buy
+24,332
New +$230K ﹤0.01% 2060

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Tudor Investment Corp's PTGX Position: Q1 2026 in Review

Tudor Investment Corp sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 7,718 shares — an estimated $683K sold.

Tudor Investment Corp first reported a position in PTGX in Q3 2022 and held it in 8 quarters. The position peaked at $2.06M in Q1 2025. 318 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Tudor Investment Corp reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Tudor Investment Corp sold 7,718 Protagonist Therapeutics shares in Q1 2026, an estimated $683K.
  • Tudor Investment Corp first reported a position in Protagonist Therapeutics in Q3 2022 and held it in 8 quarters.
  • Tudor Investment Corp's Protagonist Therapeutics position peaked at $2.06M in Q1 2025.
  • 318 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.